To demonstrate that JAK2 inhibition is detrimental to HPV+ cervical cancer cells, we utilised the potent, well-characterised JAK1/2 inhibitor ruxolitinib, which has been approved for the treatment of Polycythemia Vera (PV) [22], and the JAK2 inhibitor fedratinib, which is currently in Phase III trials for myeloproliferative disorders, were utilised to inhibit JAK2 in HPV+ cervical cancer. Here, JAK2 is linked to myeloproliferative disorder.